Nicola Flaum
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Nicola Flaum has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Dafydd Gareth Evans
Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, Manchester, UK
14 shared publications - Emma J. Crosbie
University of Manchester
8 shared publications - Emma Roisin Woodward
Manchester Centre for Genomic Medicine, Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom
6 shared publications - Richard John Edmondson
Manchester Academic Health Science Center (MAHSC) Manchester UK
4 shared publications - Eleanor Roberts
Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK
3 shared publications Emma J. Crosbie
Univ Manchester, Fac Biol Med & Hlth, Sch Med Sci, Div Canc Sci, Manchester, England
3 shared publications
Latest Publications
- Open Access
- 10 August 2026
- Published by Springer Nature
Breast cancer early detection - is it feasible to use breast milk as a liquid biopsy to detect breast cancer?
- 10 August 2026
- Published by Springer Nature
Open AccessBreast cancer early detection - is it feasible to use breast milk as a liquid biopsy to detect breast cancer?
- 31 July 2026
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 34 (9) , 1271-1272
Clinical implementation of polygenic risk scores—updates on ancestry-adjusted PRS and their use in practice
- 31 July 2026
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 34 (9) , 1271-1272
Clinical implementation of polygenic risk scores—updates on ancestry-adjusted PRS and their use in practice
- Open Access
- 1 April 2026
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 15 (4) , 352
Risk-reducing surgery, risk-reducing medication, and surveillance in young BRCA carriers with breast cancer: considering all the options
Risk-reducing surgery, risk-reducing medication, and surveillance in young BRCA carriers with breast cancer: considering all the options
- 1 April 2026
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 15 (4) , 352
Open AccessRisk-reducing surgery, risk-reducing medication, and surveillance in young BRCA carriers with breast cancer: considering all the options
Risk-reducing surgery, risk-reducing medication, and surveillance in young BRCA carriers with breast cancer: considering all the options
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (10) , 874-882
Survival Outcomes With or Without Risk-Reducing Mastectomy in BRCA1 and BRCA2 Pathogenic Variant Carriers
PURPOSE: Many women carrying pathogenic variants (pvs) of BRCA1 and BRCA2 genes (pv BRCA 1/2 ) elect to undergo bilateral risk-reducing mastectomy (BRRM) in the belief that it will improve their overall survival (OS). Although many are satisfied with their decision to undergo BRRM a significant minority exhibit regret. We compared long-term oncology outcomes in women with pv BRCA1/2 choosing BRRM with those choosing a program of imaging surveillance. METHODS: All participants were attendees at a regional family history/genetics service and had undergone genetic testing for pv BRCA 1/2 . Carriers of pv BRCA1/2 elected either to undergo BRRM or imaging surveillance as directed by UK national guidance. A prospective cohort design examined OS, breast cancer–specific death, and breast cancer incidence between the study groups. RESULTS: A total of 460 women elected to undergo BRRM, while 745 chose surveillance (median age, 37.2 years and 38.5 years, respectively; P = .06). Follow-up totaled 4,652 woman-years after BRRM. Overall annual incidence rate of breast cancer was 2.4%, falling to 0.15% after BRRM, a 94% reduction compared with surveillance alone (log-rank chi-square = 86.1; P < .001). There were nine occult cancers diagnosed at BRRM (2%). Breast cancer–specific deaths were similar in the BRRM and surveillance groups (two and four deaths, respectively; P = .36; 4,634 and 5,419 woman-years of follow-up, respectively). Proportionately, deaths from breast cancer were similar to deaths from ovarian cancer in both treatment groups. CONCLUSION: For women electing imaging surveillance over risk-reducing surgery, our results may offer reassurance that their breast cancer–specific survival and OS are unlikely to be compromised. However, breast cancer incidence rates are significantly reduced after BRRM compared with imaging surveillance, which may be important information for women with pv BRCA 1/2 considering BRRM.
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (10) , 874-882
Survival Outcomes With or Without Risk-Reducing Mastectomy in BRCA1 and BRCA2 Pathogenic Variant Carriers
PURPOSE: Many women carrying pathogenic variants (pvs) of BRCA1 and BRCA2 genes (pv BRCA 1/2 ) elect to undergo bilateral risk-reducing mastectomy (BRRM) in the belief that it will improve their overall survival (OS). Although many are satisfied with their decision to undergo BRRM a significant minority exhibit regret. We compared long-term oncology outcomes in women with pv BRCA1/2 choosing BRRM with those choosing a program of imaging surveillance. METHODS: All participants were attendees at a regional family history/genetics service and had undergone genetic testing for pv BRCA 1/2 . Carriers of pv BRCA1/2 elected either to undergo BRRM or imaging surveillance as directed by UK national guidance. A prospective cohort design examined OS, breast cancer–specific death, and breast cancer incidence between the study groups. RESULTS: A total of 460 women elected to undergo BRRM, while 745 chose surveillance (median age, 37.2 years and 38.5 years, respectively; P = .06). Follow-up totaled 4,652 woman-years after BRRM. Overall annual incidence rate of breast cancer was 2.4%, falling to 0.15% after BRRM, a 94% reduction compared with surveillance alone (log-rank chi-square = 86.1; P < .001). There were nine occult cancers diagnosed at BRRM (2%). Breast cancer–specific deaths were similar in the BRRM and surveillance groups (two and four deaths, respectively; P = .36; 4,634 and 5,419 woman-years of follow-up, respectively). Proportionately, deaths from breast cancer were similar to deaths from ovarian cancer in both treatment groups. CONCLUSION: For women electing imaging surveillance over risk-reducing surgery, our results may offer reassurance that their breast cancer–specific survival and OS are unlikely to be compromised. However, breast cancer incidence rates are significantly reduced after BRRM compared with imaging surveillance, which may be important information for women with pv BRCA 1/2 considering BRRM.
- 8 January 2026
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 34 (9) , 1-2
Clinical implementation of polygenic risk scores
- 8 January 2026
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 34 (9) , 1-2
Clinical implementation of polygenic risk scores
- Open Access
- 29 September 2025
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 34 (9) , 1262-1264
Clinical implementation of polygenic risk scores
- 29 September 2025
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 34 (9) , 1262-1264
Open AccessClinical implementation of polygenic risk scores
- 31 December 2024
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (4) , 577-579
High-grade serous ovarian cancer after bilateral salpingo-oophorectomy
- 31 December 2024
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (4) , 577-579
High-grade serous ovarian cancer after bilateral salpingo-oophorectomy
- Open Access
- 31 July 2024
- Published by Elsevier in Genetics in Medicine
- Vol. 26 (10) , 101230
Extended panel testing in ovarian cancer reveals BRIP1 as the third most important predisposition gene
- 31 July 2024
- Published by Elsevier in Genetics in Medicine
- Vol. 26 (10) , 101230
Open AccessExtended panel testing in ovarian cancer reveals BRIP1 as the third most important predisposition gene
- Open Access
- 25 August 2023
- Published by Elsevier in Journal of Cancer Policy
- Vol. 38, 100440
Cross-cultural adaptation of the PROFFIT Instrument to measure financial toxicity in people living with cancer within a UK population
- 25 August 2023
- Published by Elsevier in Journal of Cancer Policy
- Vol. 38, 100440
Open AccessCross-cultural adaptation of the PROFFIT Instrument to measure financial toxicity in people living with cancer within a UK population
- Open Access
- 19 May 2023
- Published by Elsevier in Genetics in Medicine
- Vol. 25 (9) , 100898
Optimization of polygenic risk scores in BRCA1/2 pathogenic variant heterozygotes in epithelial ovarian cancer
- 19 May 2023
- Published by Elsevier in Genetics in Medicine
- Vol. 25 (9) , 100898
Open AccessOptimization of polygenic risk scores in BRCA1/2 pathogenic variant heterozygotes in epithelial ovarian cancer